Research programme: nanoparticle therapeutics - MidatechAlternative Names: Gold nanoparticle encapsulated therapeutics - Midatech; Immuno-oncology TAM MTR- Midatech; Immuno-oncology vaccine MTR - Midatech; MTECHR 01; MTECHT 02; MTECHT 03; MTECHV 02; Nanoparticle bound amoxicillin - Midatech
Latest Information Update: 21 May 2015
At a glance
- Originator Midatech
- Developer Dana-Farber Cancer Institute; Midatech
- Class Cancer vaccines; Viral vaccines
- Mechanism of Action Cell wall inhibitors; Immunostimulants; RNA interference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Bacterial infections; Cancer; Viral infections
- Research Glioblastoma